Publications by authors named "Jennifer Gansert"

Claim this Profile
R
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
Jason A Chesney, Antoni Ribas, Georgina V Long, John M Kirkwood, Reinhard Dummer, Jennifer Gansert

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Antoni Ribas, Reinhard Dummer, Igor Puzanov, Ari VanderWalde, Robert H I Andtbacka, Jennifer Gansert

Cell· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Jason Chesney, Igor Puzanov, Frances Collichio, Parminder Singh, Mohammed M Milhem, Jennifer Gansert

J Clin Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Antoni Ribas, Reinhard Dummer, Igor Puzanov, Ari VanderWalde, Robert H I Andtbacka, Jennifer Gansert

Cell· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Robert H I Andtbacka, Howard L Kaufman, Frances Collichio, Thomas Amatruda, Neil Senzer, Jennifer Gansert

J Clin Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.
Eric Van Cutsem, Cathy Eng, Elzbieta Nowara, Anna Swieboda-Sadlej, Niall C Tebbutt, Jennifer Gansert

Clin Cancer Res· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
Takuji Okusaka, Masafumi Ikeda, Akira Fukutomi, Yoshikazu Kobayashi, Kazuhiro Shibayama, Jennifer Gansert

Jpn J Clin Oncol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
Ian McCaffery, Yanyan Tudor, Hongjie Deng, Rui Tang, Samuel Suzuki, Jennifer L Gansert

Clin Cancer Res· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
John Fr Robertson, Jean-Marc Ferrero, Hugues Bourgeois, Hagen Kennecke, Richard H de Boer, Jennifer L Gansert

Lancet Oncol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Marc Peeters, Timothy Jay Price, Andrés Cervantes, Alberto F Sobrero, Michel Ducreux, Jennifer Gansert

J Clin Oncol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Jean-Yves Douillard, Salvatore Siena, James Cassidy, Josep Tabernero, Ronald Burkes, Jennifer Gansert

J Clin Oncol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer.
J Randolph Hecht, Edith Mitchell, Marcus A Neubauer, Howard A Burris, Paul Swanson, Jennifer Gansert

Clin Cancer Res· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.
Roy D Baynes, Jennifer Gansert

Am J Ther· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human NKT cells express granulysin and exhibit antimycobacterial activity.
Jennifer L Gansert, Viviane Kiessler, Matthias Engele, Frederick Wittke, Martin Röllinghoff

J Immunol· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis